InMed Pharmaceuticals’ CEO Eric A. Adams joins LIVE! with Webull Corporate Connect Biotech Investment Webinar.
In addition to InMed, this series of corporate presentations included GRI Bio and Autonomix Medical.
The presentation by InMed includes updates on the company’s pharmaceutical programs in Alzheimer’s disease, age-related macular degeneration and epidermolysis bullosa. Eric Adams shares the latest preclinical data from the Alzheimer’s disease program showing how drug candidate INM-901 demonstrates promising disease-modifying effects including neuroprotection of neurons from amyloid-beta toxicity, reduced neuroinflammation and enhanced neuronal signalling via extension of neurites.
Eric Adams also talks about the next steps for the Alzheimer’s disease and age-related macular degeneration programs and partnership plans for the epidermolysis bullosa program which has completed Phase 2 clinical trials.
Original air date: May 1, 2024
